跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
REACTINE ALLERGY - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
REACTINE ALLERGY
Authorized
STANDARD
REACTINE ALLERGY
mcneil consumer healthcare division of johnson & johnson inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
87ac938a917a36de
Company
mcneil consumer healthcare division of johnson & johnson inc
Type
Standard
Approval Details
Approval Id
87ac938a917a36de
Drug Approval Canada Name
REACTINE ALLERGY
Product Name
REACTINE ALLERGY
Status
Marketed
Status Date
2020-02-06
Original Market Date
2020-02-06
Din
02486954
Drug Class
Human
Dosage Form
Syrup
Route Of Administration
Oral
Schedule
OTC
Ahfs
04:08.00
Atc Original
R06AE07 CETIRIZINE
Atc Name
r 06 ae 07
Aig Number
0122686004
Company Name
mcneil consumer healthcare division of johnson & johnson inc
Company Address
88 Mcnabb Street, Markham, Ontario, Canada, L3R 5L2
Active Ingredients
CETIRIZINE HYDROCHLORIDE
5 MG / 5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
87ac938a917a36de
Type
Standard
Back to Health Canada Approvals